Education
About Us
Working with TipRanks
Follow Us
Aspen Pharmacare Holdings Limited (APNHF)
OTHER OTC:APNHF
Earnings Data
Report Date
Mar 03, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
0.3Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted strong performance in the Commercial Pharma segment and strategic advancements in the GLP-1 space, but also revealed significant challenges in the Manufacturing sector and external pressures from tax and currency fluctuations. The sentiment leans towards being cautiously optimistic due to strong commercial performance, but with recognition of the hurdles in Manufacturing and external financial pressures.Company Guidance
Strong Commercial Pharma Growth
Commercial Pharma segment, which makes up 70-80% of turnover, showed sustained momentum with double-digit constant exchange rate revenue and EBITDA growth. The segment achieved 10% growth in constant exchange rates, with robust performances across Prescription Medicines, OTC Medicines, and Injectables.
Successful Launch of Mounjaro
The product Mounjaro, in partnership with Lilly, became the fastest-growing product in the South African market, with expectations to reach ZAR 1 billion in sales. This contributed significantly to the growth in the Africa, Middle East region.
Strong Operating Cash Flow Conversion
Aspen achieved an operating cash flow conversion rate of 147%, one of the highest in the last 5 years, demonstrating solid cash management despite revenue challenges.
GLP-1 Regulatory Progress
Aspen's GLP-1 dossier was one of only three to pass screening in Canada, indicating a strong position in the competition for entry into the GLP-1 market.
CapEx Reduction and Focus on Free Cash Flow
Aspen plans to reduce capital expenditure to ZAR 3.8 billion in FY 2026 from ZAR 5.1 billion in FY 2025, aiming to align CapEx with depreciation by FY 2027/2028, thereby improving free cash flow.
APNHF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
APNHF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Sep 03, 2025 | $5.72 | $5.64 | -1.40% |
Mar 03, 2025 | $11.98 | $11.98 | 0.00% |
Oct 02, 2024 | $11.98 | $11.98 | 0.00% |
Mar 04, 2024 | $9.98 | $10.34 | +3.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Aspen Pharmacare Holdings Limited (APNHF) report earnings?
Aspen Pharmacare Holdings Limited (APNHF) is schdueled to report earning on Mar 03, 2026, TBA (Confirmed).
What is Aspen Pharmacare Holdings Limited (APNHF) earnings time?
Aspen Pharmacare Holdings Limited (APNHF) earnings time is at Mar 03, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is APNHF EPS forecast?
Currently, no data Available